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Decreasing CB1 receptor signaling in Kupffer
cells improves insulin sensitivity in obese mice
Tony Jourdan 1,*,5, Sarah M. Nicoloro 3, Zhou Zhou 2,6, Yuefei Shen 3, Jie Liu 1, Nathan J. Coffey 1,
Resat Cinar 1, Grzegorz Godlewski 1, Bin Gao 2, Myriam Aouadi 4, Michael P. Czech 3, George Kunos 1,**
ABSTRACT
Objective: Obesity-induced accumulation of ectopic fat in the liver is thought to contribute to the development of insulin resistance, and
increased activity of hepatic CB1R has been shown to promote both processes. However, lipid accumulation in liver can be experimentally
dissociated from insulin resistance under certain conditions, suggesting the involvement of additional mechanisms. Obesity is also associated
with pro-inﬂammatory changes which, in turn, can promote insulin resistance. Kupffer cells (KCs), the liver’s resident macrophages, are the major
source of pro-inﬂammatory cytokines in the liver, such as TNF-a, which has been shown to inhibit insulin signaling in multiple cell types,
including hepatocytes. Here, we sought to identify the role of CB1R in KCs in obesity-induced hepatic insulin resistance.
Methods: We used intravenously administered b-D-glucan-encapsulated siRNA to knock-down CB1R gene expression selectively in KCs.
Results: We demonstrate that a robust knock-down of the expression of Cnr1, the gene encoding CB1R, results in improved glucose tolerance
and insulin sensitivity in diet-induced obese mice, without affecting hepatic lipid content or body weight. Moreover, Cnr1 knock-down in KCs was
associated with a shift from pro-inﬂammatory M1 to anti-inﬂammatory M2 cytokine proﬁle and improved insulin signaling as reﬂected by
increased insulin-induced Akt phosphorylation.
Conclusion: These ﬁndings suggest that CB1R expressed in KCs plays a critical role in obesity-related hepatic insulin resistance via a pro-
inﬂammatory mechanism.
Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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1. INTRODUCTION
Obesity is a risk factor for developing insulin resistance, which is
deﬁned as the inability of cells to respond normally to insulin. A
commonly held view is that in a subset of obese, insulin-resistant
individuals, b-cell dysfunction ensues, leading to decreased insulin
production, poor blood glucose regulation, and ultimately type 2 dia-
betes (T2D) [1,2]. The endocannabinoid system (ECS) is comprised of
G-protein coupled cannabinoid 1 and 2 receptors (CB1/2R), their
endogenous lipid ligands or endocannabinoids, and synthesizing and
degrading enzymes. The discovery of the ECS has triggered an
avalanche of experimental studies implicating it in a growing number
of physiological/pathological functions [3,4]. Modulation of ECS activity
both in the peripheral and central nervous systems and in various
peripheral organs with speciﬁc antagonists holds therapeutic promise
for a broad range of diseases such as inﬂammatory disorders or
obesity/metabolic syndrome, among others [4]. The mechanisms that
link obesity and insulin resistance are the subject of intensive research,
with increasing evidence for a major role of inﬂammation. Speciﬁcally,
the development of excess, including ectopic, adipose tissue (AT) is
strongly associated with chronic inﬂammation caused by inﬁltration of
activated immune cells and overproduction of pro-inﬂammatory cy-
tokines. Pro-inﬂammatory cytokines, such as TNF-a, can block insulin
receptor signaling in multiple cell types, including adipocytes and
hepatocytes [5,6]. It is well known that nonalcoholic fatty liver disease
is a strong risk factor for insulin resistance and type 2 diabetes [7], but
lipid accumulation in liver can be experimentally dissociated from in-
sulin resistance under certain conditions [8], suggesting that other
mechanisms are also involved. Liver resident macrophages, called
Kupffer cells (KCs), are thought to be the major source of hepatic
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inﬂammation [9] and appear to be involved in the regulation of multiple
aspects of liver biology [10]. We have previously established a pro-
inﬂammatory function of CB1R in macrophages [11] and CB1R
signaling is strongly involved in the development of fatty liver [12] and
insulin resistance [13,14]. Here, using a method to silence gene
expression selectively in Kupffer cells in vivo [11,15e19], we
demonstrate that knock-down of CB1R in Kupffer cells leads to
improved global insulin sensitivity by reducing inﬂammation, ROS
production and promoting mitochondria uncoupling through an in-
crease in UCP2 activity.
2. MATERIAL & METHODS
2.1. Animals and diet
The experimental protocol was approved by the Institutional Animal
Care and Use Committee of the National Institute on Alcohol Abuse and
Alcoholism, National Institutes of Health (NIH). Six-week-old male wild-
type C57BL/6 mice were obtained from Taconic Inc. (Taconic, Ger-
mantown, NY). Cnr1/ mice on a C57Bl/6J background were
generated by heterozygote breeding. Mice were maintained under a
12:12-h lightedark cycle and fed ad libitum either a high fat diet (HFD,
D12492; 60% of calories from fat, 20% from protein, and 20% from
carbohydrates; Research Diets, New Brunswick, NJ) or standard
mouse chow (NIH-31 rodent diet) for 15 weeks prior to treatment. Food
intake was assessed as the cumulative amount eaten over 7 days.
2.2. GeRPS administration by intravenous injection in vivo
The b1,3-d-glucan-encapsulated siRNA particles (GeRPs) were pre-
pared as previously described [16,17]. Brieﬂy, diet-induced obese
mice were treated with 6 doses of FITC-GeRPs by intravenous in-
jections every 3rd day for 15 days. Each dose of FITC-glucan shells
contained 0.33 mg of ﬂuorescently labeled GeRPs loaded with 1 nmol
(13.3ug) control (GCAUCAAGUCGACUGUUAA) or Cnr1 (GCAUCAA-
GAGCACUGUUAA) siRNA and 16.6 nmol Endoporter.
2.3. Glucose homeostasis
Glucose tolerance and insulin sensitivity tests (GTTs and ISTs) were
performed 24 h after the last GeRPs injection as described in [20]. A
dose of 1.5 g/kg glucose or 0.75 U/kg of insulin was injected intra-
peritoneally, and blood glucose levels were measured as previously
described [20].
2.4. Isolation of Kupffer cells and hepatocytes
Liver cells were isolated as described in [17]. Brieﬂy, after anesthesia,
the liver was ﬁrst perfused with calcium-free Hanks balanced salt
solution (HBSS, Gibco #14185-052, Gaithersburg, MD) then followed
by collagenase digestion (0.6 mg/mL collagenase from Clostridium
histolyticum [Sigma #C6885, St. Louis, MO] in HBBS containing 1 mM
CaCl2). After digestion, liver cells were released by dissociation from
the lobes and underwent several steps of ﬁltration through a 100 mm
cell strainer using ice-cold HBSS-CaCl2. Cell suspension was then
centrifuged at a speed of 50 g for 3 min at 4 C. The supernatant from
the ﬁrst centrifugation of hepatocytes was loaded on a Percoll gradient
(25% and 50%) and centrifuged for 30 min at 2300 rpm and 4 C. The
interphase ring with Kupffer cells was collected and washed 2 times
with PBS. The hepatocyte pellet obtained after the ﬁrst centrifugation
was washed 3 times in the same conditions in order to obtain the
enriched hepatocyte fraction. Cells were cultured overnight in RPMI-
1640 medium (ThermoFisher Scientiﬁc, 11875093, Waltham, MA)
supplemented with 10% FBS (ThermoFischer Scientiﬁc, 10082147,
Waltham, MA), 100 nM dexamethasone (Sigma #D-4902, St. Louis,
MO), 100 nM insulin (Gibco #12585-014, Gaithersburg, MD), and 1%
Penicillin/Streptomycin (ThermoFischer Scientiﬁc, 15140122, Wal-
tham, MA) at 37 C and 5% CO2. The following day, primary cells were
used for subsequent analyses.
2.5. Preparation of conditioned medium
Hepatocyte conditioned medium (CM) was prepared by incubating
primary hepatocytes isolated from lean or diet-induced obese (DIO)
mice for 48 h in the condition described above. KCs CM was obtained
by incubating primary KCs isolated from WT or global Cnr1/mice for
48 h in the same medium described above in the presence of 20 mg/
mL of LPS.
2.6. Serum parameters
Serum insulin was measured using the STELLUX Chemi Rodent
Insulin ELISA (ALPCO, Salem, NH), c-peptide and adiponectin were
quantiﬁed using ELISA kits according to manufacturer’s instruction
(ALPCO, Salem, NH). Circulating ALT, AST, triglycerides and total
cholesterol were quantiﬁed by colorimetric kits from BioAssay Systems
(Hayward, CA).
2.7. Liver parameters
Intrahepatic triglyceride content was determined as previously
described [11] whereas glycogen content was determined based on
the enzymatic reaction described in [21]. Tissue and cells extraction for
endocannabinoids measurement by liquid chromatographyetandem
mass spectrometry (LC-MS/MS) was performed as previously
described [11].
2.8. Immunohistochemistry
KCs were identiﬁed in liver and adipose tissue sections using anti-
bodies against F4/80 (AbD Serotec, Raleigh, NC) or Iba-1 (Wako, 019-
1974) and analyzed using a Zeiss LSM700 confocal microscope.
Immunopositivity was quantiﬁed using Image J software.
2.9. Reactive Oxygen Species (ROS) detection
ROS production in isolated KCs was determined with the DCFDA e
Cellular Reactive Oxygen Species Detection Assay Kit (Abcam,
Ab113851, Cambridge, UK) according to manufacturer’s instructions.
2.10. Assays for NF-kB p65 phosphorylation
Phosphorylation of NF-kB p65 in KCs was assessed by a phospho-
RelA/NF-kB p65 ELISA kit (R&D Systems, KVB7226, Minneapolis, MN)
according to the manufacturer’s instructions.
2.11. Immunoblotting
Cell lysis was performed in 1x RIPA buffer (Thermo-Scientiﬁc) sup-
plemented with phosphatase and protease inhibitor tablets (Roche),
2 mM Na3VO4, and 2 mM NaF. Total protein concentration was
determined with BCA assay (Thermo-Scientiﬁc) and adjusted to the
same concentration with additional lysis buffer. Proteins were sepa-
rated on SDS-PAGE (4e12% Bis-Tris or Tris-Glycin gradient gel, Bio-
Rad, Hercules, CA) and transferred onto nitrocellulose membranes.
Membranes were blocked in 3% non-fat milk in Tris-buffered saline
(TBS) with 0.1% Tween-20 (TBST) and incubated overnight at 4 C in
5% BSA TBST with primary antibody against phospho-p65 (RelA), p65,
phospho-AKTSer473, AKT (Cell Signaling #9271, #9272, 1/1000, Dan-
vers, MA, USA), UCP2 (Cell Signaling #89326, Danvers, MA), FABP4
(Abcam, Ab66682), CB1R (rabbit polyclonal antibody, Immunogenes,
Hungary), or HRP-conjugated mouse monoclonal antibody anti b-actin
(Abcam ab49900, 1/20, 000) as a loading control. Appropriate
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secondary antibody was diluted in 5% non-fat milk TBST and incu-
bated for 1 h at room temperature. Luminescent signal was generated
with Super Signal West Pico chemiluminescent substrate (Thermo-
Scientiﬁc) and detected with a membrane imager (G:BOX, Syngene).
Quantiﬁcation was performed using the analysis options of NIH Image J
software.
2.12. Real-time PCR
Total RNA extraction from liver, hepatocytes and Kupffer cells was
reverse transcribed, and real-time PCR were performed as previously
described [11]. QuantiTect Primer Assays (Qiagen, Germantown, MD)
were used to detect gene expression. Expression of a gene of interest
is reported as a relative value comparing it to the geometric average of
18S, L19, L38, and TATA box binding protein expression.
2.13. Statistics
Values are expressed as means  SEM. Data were analyzed by
Student’s t-test (GraphPad Prism v6 for Windows). Signiﬁcance was
set at P < 0.05.
3. RESULTS
3.1. In vivo Cnr1 knock-down in KCs improves glucose tolerance
and insulin sensitivity without affecting body weight or liver fat
content in obese mice
Diet-induced obese (DIO) mice were treated with ﬂuorescently labeled
GeRPs via intravenous injections every 3rd day for 15 days (Figure 1A),
resulting in their selective uptake by KCs (Figure 1B). In agreement
with previous observations [17], Using GeRPs containing a siRNA
against Cnr1 resulted in a signiﬁcant,w33% decrease in global liver
Cnr1 expression and aw50% decrease in hepatic anandamide levels
(Figure 1B). This treatment had no impact on body weight, food intake,
liver mass, or hepatic triglycerides, cholesterol, and glycogen content
(Figure 1C). Similarly, no differences were observed in terms of
circulating ALT and AST levels between groups (Figure 1C). However,
mice receiving Cnr1 siRNA displayed improved glucose tolerance and
insulin sensitivity (Figure 2A), whereas no differences between the
groups were noted regarding circulating insulin, c-peptide and adi-
ponectin (Figure 2B). Interestingly, siRNA-mediated Cnr1 knock-down
in KCs led to a signiﬁcant reduction in circulating triglycerides and total
cholesterol levels (Figure 2B) and also increased hepatic insulin re-
ceptor (Insr) and insulin degrading enzyme (Ide) gene expression
(Figure 2C). Moreover, this treatment was associated with a lower
expression of Ccl2 and Il6 but not Tnf, suggesting a decrease in liver
inﬂammation (Figure 2D). Interestingly, the number of Iba-1 positive
hepatic macrophages was similar in the 2 groups. Similarly, the gene
expression of three KCs markers, F4/80, Cd68 and C-type lectin
domain family 4 member F (Clec4f), remained unaffected (Figure 2E),
suggesting that the reduced inﬂammation was not due to a decrease in
hepatic macrophage content. Also, intravenous injection of GeRPs did
not inﬂuence the number of macrophages present in adipose tissue
(Supplementary Figure 1A) and did not inﬂuence Cnr1 expression is
this tissue (Supplementary Figure 1B).
3.2. In vivo Cnr1 knock-down in KCs reduces endocannabinoid
tone selectively in KCs
Hepatocyte and KC fractions were isolated from the liver of mice
sacriﬁced 24 h following the administration of GeRPs. The purity of the
fractions was analyzed by the expression of the hepatocyte marker
albumin (Alb) and the KC marker Clec4f [17], which showed an
enrichment of over 80% for the respective fractions (Figure 3A). As
expected, Cnr1 expression remained unchanged by GeRP treatment in
hepatocytes as these cells did not contain GeRPs, whereas it was
reduced by 80% in KCs, which was paralleled by a nearly 60%
reduction in CB1R protein levels as compared to KCs isolated from
mice treated with control GeRPs (Figure 3B). The much greater
reduction of Cnr1 in KCs compared to whole liver (see Figure 1B) is
likely due to the expression of Cnr1 in other liver cell types such as
hepatocytes [22], stellate cells [23], cholangiocytes [24], and liver
vascular endothelial cells [25], which remained unaffected due to lack
of uptake of GeRPs by these cells [15,17]. Additionally, Cnr1 knock-
down was associated with an increase in Faah and Mgll mRNA,
which encode endocannabinoid degrading enzymes, along with a
reduced anandamide and 2-arachidonoyl-glycerol content in KCs but
not in hepatocytes (Figure 3C).
3.3. In vivo Cnr1 knock-down in KCs restores insulin signaling and
induces a shift from pro-inﬂammatory M1 to anti-inﬂammatory M2
proﬁle
Similar to the improved insulin sensitivity following the treatment of
DIO mice with peripheral CB1R antagonists [20,26], insulin-stimulated
AktS473 phosphorylation was increased in KCs of mice treated with
Cnr1-GeRPs compared to control GeRPs (Figure 4A). KCs with Cnr1
knock-down displayed an increase in insulin receptor (Insr) but not in
insulin degrading enzyme (Ide) mRNA expression (Figure 4B). Cnr1
knock-down was associated with an inhibition of NF-kB activity, as
reﬂected by the reduced p65 phosphorylation observed by western
blotting and by cell-based ELISA (Figure 4C). In parallel, a shift from a
pro-to anti-inﬂammatory phenotype was indicated by lower Tnf and IL6
as well as higher Il10 and Arginase (Arg1) expression (Figure 4D).
Additionally, KCs with reduced Cnr1 expression also had a marked
reduction in Irf5, Ccl2, and Cxcl10 expression along with reduced Il-b
protein secretion (Figure 4E).
3.4. In vivo Cnr1 knock-down reduces oxidative stress markers
and increases mitochondria uncoupling in KCs
Cnr1 knock-down in KCs resulted in reduced expression of Cd14 and
Tlr4, genes encoding two receptors involved in NF-kB activation
(Figure 5A), along with downregulation of the fatty acid binding protein-
4 both at the mRNA and protein levels as well as a downregulation of
Cd68 and upregulation in sirtuin 3 (Sirt3) (Figure 5B). In parallel,
uncoupling protein 2 (UCP2) mRNA and protein were elevated in KCs
with Cnr1 knock-down, whereas Ucp1 and Ucp3 expression did not
change (Figure 5C). Together, these data suggest a link between CB1R
signaling and mitochondria uncoupling in KCs. Knock-down of Cnr1
also led to a signiﬁcant decrease in reactive oxygen species (ROS)
activity, as quantiﬁed using 20,70edichloroﬂuorescin diacetate
(DCFDA) as a probe (Figure 5D). Moreover, Cnr1 knock-down reduced
the expression of Gp91phox and p47phox, 2 subunits of the multi-
protein complex NADPH oxidase 2, and increased Adipor1 and Adi-
por2 mRNA expression, suggesting a decrease in oxidative stress
(Figure 5E).
3.5. Hepatocyte-derived endocannabinoids regulate cytokine
secretion by KCs
In order to investigate the stimuli involved in the inﬂammatory
response of KCs, we incubated KCs isolated from lean mice in pres-
ence of conditioned medium (CM) from hepatocytes isolated from lean
or obese mice. The CM from obese hepatocytes contained more
anandamide (AEA) but not 2-arachidonoyl glycerol (2-AG) than CM
from lean hepatocytes, and it triggered an increase in Cnr1 in lean KCs
which could be prevented by Cnr1-siRNA pre-treatment (Figure 6A).
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Figure 1: GeRP-mediated selective knock-down of Cnr1 in Kupffer cells in obese mice does not inﬂuence hepatic steatosis. A Protocol for 15-day GeRP treatment in
obese mice. B KCs staining (red) in liver section from an obese mouse 24 h after intravenous injection with FITC-labeled GeRPs (green) (magniﬁcation 200). Cnr1 gene expression
and AEA content in liver from DIO mice treated with control (black columns, n ¼ 10) or Cnr1-GeRPs (light grey columns, n ¼ 10). C Body weight, cumulative food intake, liver
weight, and liver TG, cholesterol, and glycogen content in obese mice treated with control or Cnr1-GeRPs. Columns and bars represent means  SEM. Signiﬁcant differences from
values in control-GeRPs treated obese mice *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 2: Cnr1 knock-down in Kupffer cells of DIO mice improves glucose tolerance, insulin sensitivity and reduces hepatic inﬂammation. A Glucose tolerance (GTT)
and insulin sensitivity test (IST) from DIO mice treated with control (black columns, n ¼ 10) or Cnr1-GeRPs (light grey columns, n ¼ 10). Points and bars are means  SEM from 2
independent experiments. Areas under the curve (AUC) from each experiment were used for statistical analyses. B Plasma concentrations of c-peptide, insulin, adiponectin
triglycerides, and total cholesterol. C Whole liver gene expression of insulin receptor (Insr) and insulin-degrading enzyme (Ide). D Whole liver gene expression of the pro-
inﬂammatory cytokines Tnf, Ccl2 and Il-6. E Hepatic macrophage histology as assessed by Iba-1 immuno-staining (scale bars: 50 mm) and whole liver gene expression of
macrophage markers F4/80, Cd68, and Clec4f. Columns and bars represent means  SEM. Signiﬁcant differences from values in control-GeRPs treated obese mice *P < 0.05,
**P < 0.01, ***P < 0.001.
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KCs incubated with the CM from obese hepatocytes secreted increased
amounts of TNFa, CCL2, IL-1b, and IL-6 compared to KCs incubated
with CM from lean hepatocytes (Figure 6B), and these changes were
CB1R-dependent as they were abrogated by Cnr1 knock-down
(Figure 6B).
3.6. Changes in inﬂammatory tone directly inﬂuence hepatocytes
response to insulin
In view of the EC-mediated increase in pro-inﬂammatory cytokine
secretion by KCs, we investigated if this could impair the insulin
response of hepatocytes. KCs isolated from WT and CB1R
/emice were
incubated with vehicle or LPS (50 ng/mL) for 48 h. LPS triggered an
increase in TNFa, IL-1b, and IL6 but not in CCL2 secretion, which was
much stronger in WT compared to CB1R-deﬁcient KCs (Figure 7A). We
then incubated primary hepatocytes from lean mice with regular me-
dium or KC conditioned medium and tested their response to insulin.
Insulin induced a robust increase in AKT phosphorylation on Ser473 in
hepatocytes maintained in regular medium or in CM from CB1R-deﬁ-
cient KCs, but its effect was abrogated in hepatocytes incubated with
CM from WT KCs (Figure 7B), suggesting that a CB1R-mediated cytokine
secretion by KCs inhibits hepatocyte insulin signaling.
4. DISCUSSION
In the present study, we demonstrated that selective silencing Cnr1 in
KCs improves hepatic insulin sensitivity in DIO mice, independent of
ectopic fat deposition. We used the GeRP technology to deliver siRNA
to KCs without affecting other hepatic cells [15e19] by taking
advantage of the micrometer-size and Dectin 1 receptor-mediated
recognition of the glucan shells [16]. Further speciﬁcity for hepatic
macrophages was ensured by using the intravenous route for the
administration of GeRPs, which limits their distribution to the liver
without affecting macrophages in other tissues including adipose tis-
sue [17]. As resident macrophages, KCs are the major source of pro-
inﬂammatory cytokines in the liver [27,28], and steatotic hepatocytes
inﬂuence the M1/M2 balance of KCs by promoting the apoptosis of
alternatively-activated M2 KCs, thus shifting their balance toward the
pro-inﬂammatory M1 phenotype [29]. CD14 has been reported as a
potential marker for necrotic liver inﬂammation, and its expression
correlates with the phagocytic function of KCs [30]. Moreover, binding
of LPS to CD14 on the KC membrane activates IKK kinases, thus
relieving the IkB-mediated inhibition of NF-kB, leading to an increase
in TNF-a secretion [31]. This, in turn, triggers monocyte inﬁltration
Figure 3: In vivo Cnr1 knock-down in Kupffer cells reduces the endocannabinoid tone in these cells. A Relative expression of Alb and Clec4f in hepatocyte and Kupffer cell
fractions, with levels in hepatocytes deﬁned as 1.0. B CB1R protein quantiﬁcation by western blot and Cnr1/Cnr2 gene expression in hepatocytes or Kupffer cells isolated from DIO
mice treated with control (black columns) or Cnr1-GeRPs (grey columns). C Gene expression for Faah and Mgll and endocannabinoid (AEA and 2-AG) quantiﬁcation in hepatocyte
and Kupffer cell fractions from DIO mice treated either with control (black columns) or Cnr1-GeRPs (grey columns). Columns and bars represent means  SEM. Signiﬁcant
differences from values in DIO mice treated with control-GeRPs, *P < 0.05, **P < 0.01, ***P < 0.001.
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through the expression of C-X-C motif chemokine 10 (CXCL10) and
Chemokine ligand 2 (CCL2) [32]. In addition, increases in the levels of
such pro-inﬂammatory cytokines in patients with non-alcoholic stea-
tohepatitis (NASH) are related to the level of CD14þ KCs [27,33,34]. In
view of the above, the decreased expression of Cd14, Tnf, Cxcl10, and
Ccl2 in KCs following Cnr1 knock-down reﬂects a decrease in their
pro-inﬂammatory polarization.
KCs are also activated by the binding of LPS or FFA to TLRs resulting in
the release of cytokines and chemokines via NF-kB signaling. The
activation of the NF-kB signaling pathway is also directly induced by
oxidative or endoplasmic reticulum (ER) stress. Several pro-
inﬂammatory cytokines, such as TNF-a, IL-1b, IL-6, C-C chemokine
receptors 2 (CCR-2), macrophage inﬂammatory protein 1 (MIP-1),
COX-2, CCL2, and intercellular adhesion molecule/vascular cell
adhesion molecule (ICAM/VCAM) are produced by the activated NF-kB
pathway [35,36], and systemic inhibition of NF-kB reduces hepatic
inﬂammation and improves insulin resistance [37]. Here, we found a
drastic inhibition of NFkB activation after Cnr1-knockdown in KCs,
partially explaining the associated decrease in the expression of pro-
inﬂammatory markers such as Tnf, Ccl2, Cxcl10, Il6, and IL-1b. The
degree of NF-kB inhibition and the associated reduction in cytokine
release and insulin sensitization following Cnr1 knock-down were
similar to those reported following a KC-speciﬁc knock-down of NF-kB
[17]. This suggests that CB1Ris a major upstream signal involved in
NF-kB activation in KCs.
The transcription factor interferon regulatory factor 5 (Irf5) plays an
important role in polarizing macrophages towards an inﬂammatory
phenotype and promoting insulin resistance and hepatic ﬁbrosis [38e
41]. Thus, the 50% decrease in Irf5 mRNA expression induced by Cnr1
knockdown in KCs likely contributes to their M1/M2 shift and to the
improved in vivo insulin sensitivity. This is in agreement with our
previous ﬁndings showing that IRF5 is a downstream target of CB1R in
macrophages, in which it drives the CB1R-mediated increase in TNF-a
secretion, and its in vivo knock-down in macrophages prevents the
loss of pancreatic islet b-cells and the development of type 2 diabetes
[42]. Our observations linking Irf5 expression and CB1R signaling are
also in agreement with ﬁndings that IRF5 expression in obese subjects
is negatively correlated with insulin sensitivity [38e40].
Adiponectin is known to stimulate the production of IL-10 and IL-1R
antagonist, decrease phagocytic activity, and suppress pro-
inﬂammatory cytokine production in macrophages by inhibiting NF-
kB [43e45]. Adiponectin can also promote macrophage polarization
toward an anti-inﬂammatory M2 phenotype [46,47] similarly to Cnr1
knock-down. In addition, this effect can be either direct [46] or indirect
through IL-4-mediated M2 polarization [48]. Accordingly, we found
that Cnr1 knockdown in KCs led to increased expression of both
Adipor1 and Adipor2, which was associated with increased Il10 and
Arg1 expression. AdipoR1 is abundantly expressed in macrophages
[44,49,50], whereas AdipoR2 is predominantly expressed in the liver
[51]. AdipoR1 signals via activating AMP-activated kinase (AMPK)
Figure 4: In vivo Cnr1 knock-down in KCs restores insulin signaling and promotes an anti-inﬂammatory proﬁle. A Representative Akt phosphorylation by western blot after
insulin stimulation and its quantiﬁcation. B Gene expression of insulin receptor (Insr) and insulin degrading enzyme (Ide) in isolated Kupffer cells. C Representative NF-kB
phosphorylation analysis by western blot and by cell-based ELISA kit. D Gene expression for TNFa (Tnf), IL-6 (Il6), IL-10 (Il10), and arginase 1 (Arg1) in isolated Kupffer cells.
E Gene expression for interferon regulatory factor 5 (Irf5), CCL2 (Ccl2), CXCL10 (Cxcl10), and secretion of IL-1b from isolated Kupffer cells from obese mice treated either with
control (black columns) or Cnr1-GeRPs (grey columns). Columns and bars represent means  SEM. Signiﬁcant differences from values in control-GeRPs treated DIO mice
*P < 0.05, **P < 0.01, ***P < 0.001.
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while AdipoR2 activates PPARa, both contributing to increased insulin
sensitivity [52]. Simultaneous disruption of both AdipoR1 and AdipoR2
abolished adiponectin binding and actions, resulting in increased liver
triglyceride content, inﬂammation and oxidative stress in adipose tis-
sue, and consequent insulin resistance and glucose intolerance [53]. A
similar mechanism could be at play in KCs following Cnr1 knock-down,
as indicated by the increase in both Adipor1 and Adipor2 expression.
Indeed, macrophage-speciﬁc AdipoR1 transgenic mice (AdR1-TG)
exhibit enhanced whole-body glucose tolerance and insulin sensitivity
with reduced pro-inﬂammatory cytokines, MCP-1 and TNF-a, both in
the serum and in the insulin target metabolic tissues [54].
Inﬂammation is often coupled to increased ROS production and a
pivotal source of ROS in inﬂammatory cells is the NADPH oxidase or
NOX [55]. Rapid release of ROS in response to LPS and other microbial
stimuli in KCs and other macrophages occurs mainly through the
isoform NOX2 [56]. Upon activation, NOX2 will produce superoxide, a
major form of ROS that signals to redox-sensitive targets [57e59].
UCP2 has been considered in the pathogenesis of NAFLD since its
identiﬁcation [60,61]. In this condition, KCs and other macrophages
have diminished UCP2, which could be attributed to the increased
oxidative stress seen in fatty liver [62]. In our study, we observed that
Cnr1 knock-down in KCs led to an increase in Ucp2 expression without
any changes in Ucp1 or Ucp3 expression, suggesting that the reduction
in ROS production we observed was due, at least partially, to the
uncoupling of the mitochondrial respiratory chain, especially since
macrophages isolated from Ucp2/ mice were reported to generate
more ROS than those from wild-type mice [63]. The observed
reduction in the expression of Fabp4 in CB1R-deﬁcient KCs can also
contribute to reduced oxidative stress, as it was recently shown that
inhibition or genetic deletion of FABP4/aP2 in macrophages caused an
increase in UCP2, resulting in decreased ER stress and a UCP2-
dependent reduction in ROS production [64]. This is in agreement
with previous ﬁndings where Leishmania donovani infection in mac-
rophages was associated with a strong upregulation of UCP2 and a
strong reduction in ROS generation [65]. Furthermore, in agreement
with our ﬁndings, it was recently shown that lower FABP4 can induce
Sirt3 expression, which was linked to a decrease in ROS production
and an anti-inﬂammatory phenotype in macrophages [66].
Finally, experiments using conditioned media from LPS-stimulated KCs
implicated endocannabinoids in triggering the secretion of pro-
inﬂammatory cytokines by KCs, which then could act on neighboring
hepatocytes to inhibit insulin signaling. Previously, we have demon-
strated that LPS causes a robust, >10-fold increase in anandamide
synthesis in RAW264.7 macrophages [67], which could act as auto-
crine mediator on CB1R located on the same cell. Indeed, the
involvement of CB1R in cytokine release by KCs is supported by the
reduced cytokine release and corresponding loss of biological activity
of medium conditioned with CB1R-deﬁcient KCs, as illustrated in
Figure 7. These observations suggest a cross-talk between KCs and
hepatocytes, which could trigger hepatic insulin resistance.
To conclude, the data presented demonstrate that CB1R signaling in
KCs plays an important role in hepatic insulin resistance independently
of ectopic fat in the liver or adipose tissue inﬂammation. Given the
documented role of hepatocyte CB1R in insulin resistance [14], our
study reinforces the importance CB1R expressed by different types of
liver cells in glycemic control and further highlights the therapeutic
potential of peripheral CB1R blockade in the metabolic complications of
obesity.
Figure 5: In vivo Cnr1 knock-down in KCs reduces oxidative stress. A Gene expression for CD14 and TLR4 in Kupffer cells. B Representative western blot showing FABP4
protein levels in Kupffer cells isolated from obese mice treated with either control or Cnr1-GeRPs and gene expression for Fabp4 and Sirtuin-3 (Sirt3). C UCP-2 protein and gene
expression along with Ucp1 and Ucp3 gene expression in Kupffer cells. D Reactive Oxygen Species (ROS) produced by Kupffer cells isolated from obese mice treated with either
control or Cnr1-GeRPs. E Gene expression for Gp91phox, p47phox, AdipoR1, and Adipor2 in isolated Kupffer cells from obese mice treated either with control (black columns) or
Cnr1-GeRPs (grey columns). Columns and bars represent means  SEM. Signiﬁcant differences from values in control-GeRPs treated obese mice *P < 0.05, **P < 0.01,
***P < 0.001.
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Figure 6: KCs secretary response is inﬂuenced by changes in endocannabinoid tone. A Endocannabinoid content in conditioned medium from hepatocytes isolated from lean
(blue columns) or obese mice (green columns) and Cnr1 expression in Kupffer cells incubated for 24 h in these conditioned media in presence of either control or Cnr1 siRNA.
B Effect of conditioned medium on Kupffer cells secretion of TNF-a, CCL2, IL-1b, and IL-6 after 24 h. Columns and bars represent means  SEM from 3 individual experiments
with n ¼ 4 per condition. Signiﬁcant differences from values in Veh-treated Kupffer cells (white columns) *P < 0.05, **P < 0.01, ***P < 0.001 or control siRNA treated cells (blue
or green columns) #P < 0.05, ##P < 0.01, ###P < 0.001.
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